Healthcare / Drug Manufacturers - GeneralXETRA
$345.20
-10.20 (-2.87%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 23% · confianza 25%
FCF escenarios
weak_data · normalized FCF $13.1B · quality 74.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
42/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$274.6B
P/E
19.6x
↓EV/EBITDA
14.0x
↑ROE
38.1%
↑Gross Margin
73.7%
↑Debt/Equity
0.98
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.3%
FCF CAGR
-0.4%
FCF margin
20.6%
FCF / Net income
1.01x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $63.36B · net income $12.88B · FCF $13.07B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $63.36B | $63.36B | $62.40B | $60.44B | $65.81B |
| Net Income | $12.88B | $12.88B | $8.28B | $11.50B | $12.42B |
| EBITDA | $21.70B | $21.70B | $16.62B | $18.54B | $20.86B |
| EPS | 16.04 | 16.04 | 10.31 | 14.31 | 15.37 |
| Gross Margin | 73.7% | 73.7% | 73.9% | 72.9% | 70.0% |
| Operating Margin | 29.2% | 29.2% | 21.5% | 25.5% | 26.6% |
| Net Margin | 20.3% | 20.3% | 13.3% | 19.0% | 18.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.98 | 0.98 | 1.14 | 1.05 | 0.95 |
| Current Ratio | 1.38 | 1.38 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.07B | $13.07B | $15.09B | $11.45B | $13.25B |
| Returns | |||||
| ROE | 38.1% | 38.1% | 26.1% | 39.2% | 44.4% |
| Valuation | |||||
| P/E | 19.62 | 19.62 | — | — | — |
| EV/EBITDA | 14.04 | 14.04 | — | — | — |
| P/B | 8.20 | 8.20 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 1.5% | 1.5% | 3.2% | -8.2% | — |
| EPS Growth | 55.6% | 55.6% | -28.0% | -6.9% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
24.1%
EPS terminal req.
$30.63
Spread vs growth
31.5%
5Y implied EPS CAGR
18.2%
EPS terminal req.
$37.06
Spread vs growth
37.3%
10Y implied EPS CAGR
14.0%
EPS terminal req.
$59.69
Spread vs growth
41.5%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+14.8%
Start / end P/E
30.0x → 21.5x
EPS bridge
10.31 → 16.04
Residual
-15.6%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.